

## INFORMATION DISCLOSURE STATEMENT

Applicant : Cowing, Carol O.  
App. No : 09/809,158  
Filed : March 15, 2001  
For : METHOD TO ENHANCE THE  
IMMUNOGENICITY OF AN  
ANTIGEN  
Examiner : Karen A. Canella  
Art Unit : 1643

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 3 references to be considered by the Examiner. Also enclosed are 3 references as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: November 18, 2005

By: 

Marina L. Gordey  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(805) 547-5580

11/22/2005 FMEYKI1 00000018 09809158

01 FC:1806

180.00 OP



DocSet No.: LANCELL.002CP1

November 18, 2005

Page 1 of 1

Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER  
INFORMATION DISCLOSURE STATEMENT**

Applicant : Cowing, Carol O.  
App. No : 09/809,158  
Filed : March 15, 2001  
For : METHOD TO ENHANCE THE  
IMMUNOGENICITY OF AN ANTIGEN  
Examiner : Karen A. Canella  
Art Unit : 1643

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

November 18, 2005

(Date)


Marina L. Gordey, Reg. No. 52,950


**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
  - (X) Listing 3 references.
  - (X) Enclosing 3 references.
- (X) A check in the amount of \$180.00 to cover the above fee is enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

  
Marina L. Gordey  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(805) 547-5580

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	09/809,158
Filing Date	March 15, 2001
First Named Inventor	Cowing, Carol O.
Art Unit	1643
Examiner	Karen A. Canella
Attorney Docket No.	LANCELL.002CP1

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
KAC	1	5,910,306	06-08-1999	Alving et al.	
KAC	2	6,797,276 B1	09-28-2004	Glenn et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
KAC	3	WO 98/20734	05-22-1998	U.S. Government		


**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>

1970438:vr100405

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.



PATENT

Case Docket No. LANCELL.002CPI  
Date: November 17, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Cowing, Carol O.  
Appl. No. : 09/809,158  
Filed : March 15, 2001  
For : METHOD TO ENHANCE THE  
IMMUNOGENICITY OF AN  
ANTIGEN  
Examiner : Canella, Karen A.  
Group Art Unit : 1642

I hereby certify that this correspondence and all  
marked attachments are being deposited with the  
United States Postal Service as first class mail in  
an envelope addressed to: Commissioner for  
Patents, Mail Stop Amendment, P.O. Box 1450,  
Alexandria, VA 22313-1450, on

November 17, 2004  
(Date)

Marina L. Gordey, Reg. No. 52,950

TRANSMITTAL LETTER

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with eight (8) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Marina L. Gordey  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(805) 547-5580

**INFORMATION DISCLOSURE STATEMENT**

Applicant	:	Cowing, Carol O.
App. No.	:	09/809,158
Filed	:	March 15, 2001
For	:	METHOD TO ENHANCE THE IMMUNOGENICITY OF AN ANTIGEN
Examiner	:	Canella, Karen A.
Group Art Unit	:	1642

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 8 references that are also enclosed.

This Information Disclosure Statement is being filed before the mailing date of a final action under 37 C.F.R. § 1.113 and before the mailing date of a Notice of Allowance under § 1.311. A certification under 37 C.F.R. § 1.97(e) is set forth below. Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

**CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(2)**

I hereby certify that no item of information contained in this Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R.


Appl. No. : 09/809,158  
Filed : March 15, 2001

Docket No. LANCELL.002CP1  
Customer No. 20,995


§ 1.56(c) more than 30 days prior to the filing of this Information Disclosure Statement.

Dated: November 17, 2004

Respectfully submitted,  
KNOBBE, MARTENS, OLSON & BEAR, LLP

By:   
Marina L. Gordey  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(805) 547-5580

O:\DOCS\MXG\MXG-6309.DOC:vr  
111104



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
LANCELL002CP1APPLICATION NO.  
09/809,158INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Cowing, Carol O.FILING DATE  
March 15, 2001GROUP  
1842

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
KAC	1	4,353,896	10/12/1982	Levy			
KAC	2	4,455,142	06/19/1984	Martins et al.			
KAC	3	5,487,897	01/30/1996	Polson et al.			
KAC	4	5,564,312	08/05/1997	Andrulis, Jr. et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
KAC	5	0 308 210	03/22/1989	Europe				
KAC	6	2 145 931	04/11/1985	Great Britain				

EXAMINER  
INITIAL

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

KAC	7	Enk A.H. et al. 1993 "An essential role of Langerhans cell-derived IL-1 $\beta$ in the initiation of primary immune response in skin," <i>J. Immunol.</i> 150:3698-3704.
KAC	8	Supplemental European Search Report from corresponding application EP 98 91 8392, mailed on October 21, 2004.

O:\DOCS\WGMXG-6307.DOC111104

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

## INFORMATION DISCLOSURE STATEMENT

Applicant : Cowing  
App. No. : 09/809,158  
Filed : March 15, 2001  
For : METHOD TO ENHANCE THE  
IMMUNOGENICITY OF AN ANTIGEN  
Examiner : Canella, K.  
Group Art Unit : 1642

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 3 references that are also enclosed.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(c)(2) before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

12/17/2003 HALI11 00000023 09809158

02 FC:1806

180.00 OP

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 12/11/03

By: Mark R. Benedict

Mark R. Benedict  
Registration No. 44,531  
Attorney of Record  
Customer No. 20,995  
(949) 760-0404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
LANCELL.002CP1APPLICATION NO.  
09/809,158INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
CowingFILING DATE  
March 15, 2001GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
KAC	1.	Koyama et al. (1989) Effect of systemic and topical application of testosterone propionate on the density of epidermal Langerhans cells in the mouse. J. Invest. Dermatol. 1:86-90 (Abstract).
KAC	2.	Murphy et al. (1998) Tropical tretinoin replenishes CD1a-positive epidermal Langerhans cells in chronically photodamaged human skin. J. Cutan. Pathol. 1:30-4 (Abstract).
KAC	3.	Ragg et al. (1994) Lagerhans cell migration patterns from sheep skin following topical application of carcinogens. Int. J. Exp. Pathol. 1:23-8.

O:\DOCS\MXG\MXG-4192.DOC:vb  
121003

EXAMINER	/Karen A. Canella, Ph.D./	DATE CONSIDERED	10/02/2006
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			